Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer | Journal for ImmunoTherapy of Cancer
Pexa-Vec (JX-594) | SILLAJEN
VX2 rabbit tumor model development for use with JX-594. (A) Replicative... | Download Scientific Diagram
Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets | Journal of Experimental & Clinical Cancer Research | Full Text
Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy: Molecular Therapy
Genetically engineered virus kills liver cancer and significantly prolongs life
Biomedicines | Free Full-Text | Oncolytic Virotherapy for Cancer: Clinical Experience | HTML
Viruses as nanomedicine for cancer | IJN
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial - The Lancet Oncology
Healing Viruses
The immune microenvironment and progression of immunotherapy and combination therapeutic strategies for hepatocellular carcinoma
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer | Nature Medicine
Frontiers | Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment | Immunology
Frontiers | Delivery and Biosafety of Oncolytic Virotherapy | Oncology
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. - Abstract - Europe PMC
The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma in: Neurosurgical Focus Volume 50 Issue 2 (2021) Journals
Jennerex and Transgene announce initiation of clinical trial in metastatic colon cancer with intravenous JX-594
Viruses as nanomedicine for cancer | IJN
Oncolytic immunotherapeutic virus in HCC: Can it compete with molecular therapies? - Journal of Hepatology
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics | Journal for ImmunoTherapy of Cancer | Full Text
Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF – topic of research paper in Biological sciences. Download scholarly article PDF and read for free on
The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers: Molecular Therapy
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer | Nature Medicine
PDF) A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma
